1. Association analyses between the variants of SNAP25, SV2C and ST3GAL2 and the efficacy of botulinum toxin A in the treatment of the primary Meige syndrome
- Author
-
Wen-Qi Wu, Kai Li, Lu-Lu Chu, Ting-Ting Shen, Yang Li, Ying-Ying Xu, Qi-Lin Zhang, Chun-Feng Liu, Jing Liu, Xu-Ping Zhou, and Wei-Feng Luo
- Subjects
Botulinum toxin A ,Meige syndrome ,Cervical dystonia ,SNAP25 ,SV2C ,ST3GAL2 ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Objective: Individual differences were observed in the clinical efficacy of Botulinum toxin A (BoNT-A) in the treatment of the primary Meige syndrome. Our study aimed to explore the potential associations between the clinical efficacy of BoNT-A in the treatment of the primary Meige syndrome and variants of SNAP25, SV2C and ST3GAL2, which are involving in the translocation of the BoNT-A in vivo. Methods: Patients with the primary Meige syndrome treated with BoNT-A were enrolled. Clinical efficacy was evaluated by the maximum improvement rate of motor symptoms and the duration of efficacy. Variants of SNAP25, SV2C and ST3GAL2 were obtained by Sanger sequencing. Another cohort diagnosed with primary cervical dystonia was also enrolled in the replication stage. Results: Among the 104 primary Meige syndrome patients, 80 patients (76.9%) had a good efficacy (the maximum improvement rate of motor symptoms ≥30%) and 24 (23. 1%) had a poor (the maximum improvement rate of motor symptoms
- Published
- 2024
- Full Text
- View/download PDF